诉讼基本情况 - 针对Savara Inc (NASDAQ: SVRA) 的证券集体诉讼正在审理中 该诉讼由Pomerantz LLP律师事务所提起 [1] - 诉讼旨在为在2024年3月4日至2025年5月23日期间因涉嫌证券欺诈而遭受损失的股东挽回损失 [2] 诉讼指控细节 - 指控称被告在关于治疗肺泡蛋白沉积症的MOLBREEVI生物制剂许可申请中 做出了虚假陈述和/或隐瞒了相关信息 [3] - 具体指控包括MOLBREEVI的化学、制造和/或控制方面缺乏足够信息 导致美国FDA不太可能以当前形式批准其申请 [3] - 上述情况使得Savara公司不太可能在其向投资者承诺的时间框架内完成MOLBREEVI的申请提交 [3] - MOLBREEVI监管批准的延迟增加了公司需要筹集额外资金的可能性 [3] - 因此 被告的公开陈述在所有相关时间点均存在重大虚假和误导性 [3]

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission-for ...

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 21, 2025 /PRNewswire/ --Â Levi &Â Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: SOURCE Levi & Ko ...

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SVRA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is November 7, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the ...

诉讼核心信息 - 律师事务所Levi & Korsinsky, LLP就Savara Inc (NASDAQ: SVRA) 的证券集体诉讼通知投资者 [1] - 诉讼旨在为在2024年3月4日至2025年5月23日期间因涉嫌证券欺诈而遭受损失的Savara投资者挽回损失 [1] - 投资者申请作为首席原告的截止日期为2025年11月7日 [3] 诉讼指控细节 - 指控称被告作出了虚假陈述和/或隐瞒了以下事实：治疗肺泡蛋白沉积症的MOLBREEVI生物制剂许可申请缺乏关于其化学、制造和控制的足够信息 [2] - 因此美国FDA不太可能以当前形式批准MOLBREEVI的BLA [2] - 上述情况使得Savara不太可能在其向投资者承诺的时间框架内完成MOLBREEVI BLA的提交 [2] - MOLBREEVI监管批准的延迟增加了公司需要筹集额外资金的可能性 [2] - 因此被告的公开陈述在所有相关时间点均存在重大虚假和误导性 [2] 律师事务所背景 - Levi & Korsinsky在过去20年间已为受损股东追回数亿美元并建立了赢得高风险案件的记录 [4] - 该律所拥有70多名员工团队连续七年被ISS证券集体诉讼服务评为美国顶级证券诉讼律所之一 [4]

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=172046&from=3 CLASS PERIOD: March 4, 2024 to May 2 ...

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=171657&from=3 CLASS PERIOD: March 4, 2024 to May 2 ...